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ABSTRACT
Introduction: Emerging evidence suggests that
patient-reported outcome (PRO)-specific information
may be omitted in trial protocols and that PRO results
are poorly reported, limiting the use of PRO data to
inform cancer care. This study aims to evaluate the
standards of PRO-specific content in UK cancer trial
protocols and their arising publications and to
highlight examples of best-practice PRO protocol
content and reporting where they occur. The objective
of this study is to determine if these early findings are
generalisable to UK cancer trials, and if so, how best
we can bring about future improvements in clinical
trials methodology to enhance the way PROs are
assessed, managed and reported. Hypothesis: Trials in
which the primary end point is based on a PRO will
have more complete PRO protocol and publication
components than trials in which PROs are secondary
end points.
Methods and analysis: Completed National Institute
for Health Research (NIHR) Portfolio Cancer clinical
trials (all cancer specialities/age-groups) will be
included if they contain a primary/secondary PRO end
point. The NIHR portfolio includes cancer trials,
supported by a range of funders, adjudged as high-
quality clinical research studies. The sample will be
drawn from studies completed between 31 December
2000 and 1 March 2014 (n=1141) to allow sufficient
time for completion of the final trial report and
publication. Two reviewers will then review the
protocols and arising publications of included trials to:
(1) determine the completeness of their PRO-specific
protocol content; (2) determine the proportion and
completeness of PRO reporting in UK Cancer trials and
(3) model factors associated with PRO protocol and
reporting completeness and with PRO reporting
proportion.
Ethics and dissemination: The study was approved
by the ethics committee at University of Birmingham
(ERN_15-0311). Trial findings will be disseminated via
presentations at local, national and international
conferences, peer-reviewed journals and social media
including the CPROR twitter account and UOB
departmental website (http://www.birmingham.ac.uk/
cpro0r).
Trial registration number: PROSPERO
CRD42016036533.
INTRODUCTION
Patient-reported outcome (PRO) measures
are validated questionnaires, self-completed
by patients, that provide the patient perspec-
tive on physical, functional and psychological
Strengths and limitations of this study
▪ Our review will assist the scientific community in
determining how best to improve the way
patient-reported outcomes (PROs) are assessed,
managed and reported in future cancer trials.
▪ Our review will provide original data regarding
the potential factors associated with PRO proto-
col quality and PRO reporting.
▪ The review will be limited to UK-led studies
adopted to the National Institute for Health
Research portfolio, which may limit generalisabil-
ity of the results.
▪ Our selection criteria may lead to a cohort of
studies that are not fully representative of the
field as the trials may, on average, be of a higher
quality than those found in the field (they are
studies that have successfully completed) and
they are more likely to be trials that have yielded
a positive result (due to publication bias by
journals).
▪ Our search criteria may be more likely to identify
and obtain the required documents for non-
industry sponsored trials, as the protocols of
industry trials may be more likely to be confiden-
tial due to commercially sensitive information
being included in them.
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consequences of treatment and the degree and impact of
disease symptoms.1 The value of using PROs in cancer
clinical trials has been emphasised by major international
health-policy and regulatory authorities and by patients
with cancer.2–4 PRO results can inform patient choice
and clinician decision-making, health technology assess-
ment, health economic evaluations, labelling claims and
healthcare policy and commissioning.5–8
Patients with cancer value PRO information and may
use it to inform complex healthcare decisions.9 10 For
instance, PRO trial results can help patients to assess
whether survival beneﬁts of a new drug outweigh poten-
tial side effects or may assist patients and their clinicians
in choosing between treatment options offering similar
survival rates.11–15 Given their importance: (1) details
regarding PRO assessment should be included in the
trial protocol, to ensure appropriate data collection and
management;16 17 and (2) PRO results should be fully
reported in arising trial publications, to enable timely
access by patients, clinicians and policymakers and facili-
tate integration of ﬁndings into clinical practice.18
However, our recent review of 75 National Institute for
Health Research (NIHR) Health Technology Assessment
trials19 suggests important PRO information is frequently
omitted from trial protocols, even where a PRO is the
primary outcome of the study. This may lead to impaired
data collection and result in poor quality PRO data,
therefore limiting the potential of PRO ﬁndings to
effectively inform patient care.20 Furthermore, inter-
national research suggests PRO results are poorly
reported in trial publications or may not be reported at
all.18 21 22 Thus, valuable information that may have a
signiﬁcant impact on treatment decision-making and
outcomes may not be available to patients, clinicians
and researchers. This would represent a waste of limited
healthcare and research resources, which is unethical,
and also devalues the contribution of trial participants
who spend time and effort providing PRO data.23
This study aims to evaluate the standards of PRO-speciﬁc
content in UK cancer trial protocols and their arising pub-
lications. The speciﬁc study objectives are to:
▸ Determine the completeness of PRO-speciﬁc protocol
content in UK cancer trials.
▸ Determine the proportion of trials reporting PRO
results, that is, the number of trials including PROs
in their protocol and subsequently reporting the
results in their principal publication.
▸ Determine the completeness of PRO reporting.
▸ Model factors associated with PRO protocol and report-
ing completeness, and with PRO reporting proportion.
▸ Highlight examples of best-practice PRO protocol
content and reporting where they occur.
HYPOTHESES
▸ Trials in which the primary end point is based on a
PRO will have more complete PRO protocol and pub-
lication components than trials in which PROs are
secondary end points.
▸ Publications of trials with more complete PRO proto-
col components will have more complete reporting of
PROs than those of trials with less complete PRO
protocol components.
METHODS AND ANALYSIS
Inclusion and exclusion criteria
Completed NIHR Portfolio Cancer clinical trials (all
cancer specialities/age groups) will be included if they
contain a primary/secondary PRO end point. The NIHR
portfolio includes UK-led trials, supported by a range of
funders, adjudged as high-quality clinical research
studies.24 The sample will be drawn from studies com-
pleted between 31 December 2000 and 1 March 2014
(n=1141) to allow sufﬁcient time for completion of the
ﬁnal trial report and publication (ﬁgure 1).
Non-randomised trials and trials not completed by the
cut-off date (1 March 2014) will be excluded.
Protocol/publication sourcing
Two investigators (TK/KA) will independently search
the NIHR Portfolio for eligible trials; disagreements will
be resolved through discussion with a third or fourth
reviewer (DK/MC). The most up-to-date trial protocol
(ﬁnal version approved by ethics) will be retrieved for
review. Following a pilot, it was determined that trial
registry information was frequently incomplete, there-
fore we plan to search for protocols using a range of
resources outlined below:
1. NIHR portfolio; ISRCTN
2. EU Clinical Trials Register/EUdract
3. Clinical trials.gov
4. UKNCRN/UK Clinical trials gateway
5. Funder/Sponser
6. Google
For each protocol sourced, we will retrieve all related
subsequent reports/publications either via a direct
email to the named trial contact or using recognised
bibliographic databases (eg, MEDLINE, Embase,
CINAHL).
Publications will be sourced via direct contact with the
corresponding/ﬁrst author, or via the Patient-Reported
Outcome Measures Over Time In Oncology
(PROMOTION) Registry (http://promotion.gimema.it/),25
Embase; MEDLINE; Cinahl+; PsycINFO and Cochrane
databases.
Data extraction
Two investigators (TK/KA) will independently extract
the following data for each included trial, using a prede-
signed data extraction form: trial demographics, year of
protocol, the name(s)/type(s) of PRO(s) used, whether
a PRO was a primary and/or secondary outcome, trial
sample size, trial setting (national/international),
number of research sites, funding source (including aca-
demic and industry supported), cancer specialty and age
group (adult, teenage and young adult (TYA, 13–
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24 years inclusive), paediatric). The following data will
be extracted from included trial reports/publications
and recorded on the same form: year of ﬁnal report/
publication(s), number of publications and journal/pub-
lication source(s).
Checklists
Completeness of the PRO-speciﬁc content of trial proto-
cols will be assessed using a PRO protocol checklist19
detailing 33 PRO-speciﬁc items that are recommended
in the literature for inclusion in a trial protocol.
Completeness of general sections within each protocol
will be assessed using the SPIRIT checklist, as a proxy
measure of the overall strength of the protocol.17 26
Completeness of PRO reporting will be evaluated using
the CONSORT PRO extension checklist.27 We will also
explore the use of the ISOQOL reporting standards
checklist. General quality of reporting will be assessed by
the 37-item 2010 CONSORT checklist.28
Protocol and publication review
Trial protocols and their primary publications (presenting
the principal study ﬁndings) will be evaluated in the
review/analysis. Subsequent trial publications focused on
PRO-speciﬁc results will also described. Two investigators
(TK/KA) will independently assess the content of the
included protocols using the SPIRIT and PRO protocol
checklists. The investigators will independently assess con-
sistency of the trial protocol/registration information with
all subsequent publications to identify any discrepancies in
the reporting of PRO trial outcomes. Unreported out-
comes will be deﬁned as those prespeciﬁed in the trial
protocol/registration information but not reported in any
subsequent publications.29 If a report is available, investiga-
tors will assess its completeness using the CONSORT and
CONSORT-PRO Extension checklists (and the ISOQOL
reporting standards checklist if applicable/feasible).30
Levels of investigator agreement will be determined for
each checklist. Disagreements will be resolved through dis-
cussion with a third investigator (DK/MC).
Figure 1 Schematic breakdown of trial search results of interventional clinical cancer trials between 1 March 2014 and 31
December 2000. PRO, patient-reported outcome.
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Quantitative data analysis
Descriptive analyses will be conducted on the number of
SPIRIT and PRO checklist items present in the included
trial protocols; on the proportion of incomplete PRO
reporting and, where appropriate, on the number of
CONSORT and CONSORT-PRO Extension checklist
items present in the included in the principal trial publi-
cation. CONSORT-PRO checklist scores will also be
described for those trials with subsequent PRO-speciﬁc
publications and time from principal publication to sec-
ondary PRO publication will be reported.
PRO protocol and reporting models
To explore factors associated with the inclusion of
PRO-speciﬁc protocol items, we will perform a prespeci-
ﬁed multiple regression analysis in which the dependent
variable will be the ‘PRO protocol checklist score’ and the
independent variables will be (1) year of protocol, (2)
whether the PRO was named as a primary or secondary
outcome, (3) cancer specialty, (4) participant age group
(adult/TYA/paediatric), (5) trial sample size, (6) funding
source and (7) the SPIRIT checklist score. We will also
perform a logistic regression, using the same covariates, in
which the dependent variable will be ‘PRO trial results
reported in the principal trial publication (yes/no)’.
To explore factors associated with the inclusion of
CONSORT-PRO Extension reporting items, we will
perform a prespeciﬁed multiple regression analysis in
which the dependent variable will be the
‘CONSORT-PRO checklist score’ and the independent
variables will be (1) the year of publication, (2) whether
the PRO was named as a primary or secondary outcome,
(3) whether there were single or multiple reports, (4)
trial sample size, (5) funding source, (6) journal/publi-
cation source, (7) the standard CONSORT checklist
score, and (8) the PRO protocol checklist score.
Where the sample size allows, we will attempt to conduct
parallel exploratory analysis in which trials with a PRO
primary end point are analysed separately from those with
secondary PRO end points. All models and covariates will
be ﬁnalised prior to the data analysis phase.
Sample size calculation
A minimum of 80 protocols and publications will be
required to satisfy the sample size requirement for the
regression analyses (10 per covariate)31 of trials regard-
less of whether PROs are primary or secondary end
points.
Ethics and dissemination
The study was approved by the ethics committee at the
University of Birmingham (ERN_15-0311) in September
2015. The results of this study will be disseminated via
presentations at local, national and international confer-
ences, peer-reviewed journals and through social media
including the Centre for Patient Reported Outcomes
Research twitter account and the University of
Birmingham departmental website (http://www.
birmingham.ac.uk/cpror), and via the NCRI (including
the consumer forum), Macmillan Cancer Support and
via international cancer trials groups.
Protocol and registration
The study protocol is registered on PROSPERO
(CRD42016036533), and registration details are available
at: http://www.crd.york.ac.uk/PROSPERO/display_record.
asp?ID=CRD42016036533.
DISCUSSION
A 2015 review investigated the frequency with which
PROs (health-related quality of life) were speciﬁed in
cancer trial protocols (2000–2003, non-UK) and subse-
quently reported in the literature.21 Of the 173 included
trials, just over half (n=90) included a PRO, but only 35
of these (38%) reported the ﬁndings in an arising publi-
cation. However, no evaluation of the quality of PRO
protocol/publication content was undertaken, and so
the relationship between protocol completeness and
reporting could not be assessed.
The current review is therefore necessary to provide a
comprehensive representation of the standards of PRO
content of protocols in UK cancer clinical trials and to
assess whether addressing PRO content in protocols leads
to more complete reporting of PROs in subsequent trial
publications. Moreover, this systematic review will provide
original data regarding the potential factors associated
with PRO protocol quality and PRO reporting quality/
proportion. This information will assist the scientiﬁc com-
munity in determining how best we can bring about
methodological improvements in the way PROs are
assessed, managed and reported in future cancer trials.
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